Riding the pepTIDE — The Daily Wire on Therapeutic Peptides

An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.

Topic Sections

  • Top Shots — The most significant peptide and longevity stories ranked by overall editorial score
  • Research Signals — High-credibility scientific findings from journals, preprints, and clinical sources
  • Healing & Recovery — Tissue repair, injury recovery, and gut healing peptides including BPC-157 and TB-500
  • Growth Hormone Wire — Growth hormone secretagogues, peptide stacks, and GH axis research including Ipamorelin, CJC-1295, and MK-677
  • Metabolic & GLP-1 — Metabolic health, insulin sensitivity, and GLP-1 receptor agonist research including semaglutide and tirzepatide
  • Cognitive / Nootropic — Peptides targeting brain function, memory, neuroprotection, and cognitive enhancement
  • Skin & Cosmetic — Skin repair, anti-aging, collagen synthesis, and cosmetic peptide research including GHK-Cu and matrixyl
  • Reddit Finds — Community-sourced discussions, self-experimentation reports, and protocol threads from peptide communities
  • Contrarian Takes — Alternative viewpoints, dissenting research, and perspectives that challenge mainstream peptide narratives
  • Skeptic's Corner — Hype debunking, low-evidence alerts, and critical analysis of overstated peptide claims

Browse by Filter

  • Newest — Latest peptide and longevity stories
  • Most Credible — Highest credibility-scored stories
  • Most Edgy — High-novelty, unconventional findings
  • Most Discussed — Trending community discussions
  • Most Actionable — Direct applicability to daily health protocols
  • Lowest Risk — Stories with strong evidence, low hype
  • Research Only — Peer-reviewed and preprint studies
  • Reddit Only — Community discussion and anecdote
  • GLP-1 / Metabolic — Semaglutide, tirzepatide, and metabolic peptides
  • Healing / Recovery — BPC-157, TB-500, and repair protocols

More

  • About Riding the pepTIDE
  • Health Disclaimer
  • Submit a Source
  • Contact

Stopping Mounjaro for Colonoscopy: What Two Months Off Did to My Weight

A reader shared a personal note about taking a break from Mounjaro (often abbreviated MJ) because they needed to stop the drug to prepare for a colonoscopy, then had a follow-up colonoscopy two weeks later. They were off the medication for about two months, and then decided to stay off a bit longer. The writer was taking a 2.5 mg dose and had been losing weight on that dose for about 18 months before the break. Mounjaro is the brand name for tirzepatide. It’s a prescription drug that mimics natural signals in the body that help control appetite and blood sugar. In plain terms, it acts like hormones your gut releases after you eat to tell your brain you’re full and to slow how fast your stomach empties. People take it for type 2 diabetes and many use it off-label or by prescription for weight loss because it lowers hunger and often leads to steady weight reduction. The snippet is a single-person report, basically an informal anecdote, not a clinical study. The person reports being on a low dose (2.5 mg) for a long stretch and losing weight during that time, then stopping for medical procedures and noticing whatever changes afterward. There are no numbers given for how much weight they lost or how their weight changed during the break. So we can’t draw firm conclusions about how stopping Mounjaro will affect anyone else. It’s useful as a personal experience but not evidence that applies broadly. Why does this matter? Lots of people are using tirzepatide or similar drugs and wonder what happens if they need to pause treatment for medical reasons, surgery, or supply issues. Personal stories can signal common questions: will weight come back quickly? Will appetite return? Do you need to change your eating plan? For someone on a maintenance dose who’s been stable, this anecdote suggests breaks happen and people notice effects — but it doesn’t tell you the pattern or timeline to expect. Important caveats: this is a single, self-reported experience. It doesn’t replace medical advice. Stopping or starting tirzepatide should be discussed with a prescribing clinician, especially before procedures. Possible side effects and risks include nausea, gastrointestinal symptoms, low blood sugar when used with some diabetes drugs, and rare but serious concerns clinicians monitor for. The drug’s official indications, dosing, and safety monitoring are set by regulatory agencies and doctors; any decision to pause therapy should follow medical guidance. Bottom line: one person’s short break from Mounjaro after long-term use offers a glimpse into real-world experiences, but it’s an anecdote, not proof, and anyone considering changes to their medication should talk with their doctor.

Source: r/Mounjaro

Read full story

Back to Riding the pepTIDE